Avadel Pharma (NASDAQ: AVDL) reported Q2 EPS of ($0.14), $0.04 better than the analyst estimate of ($0.18). Revenue for the quarter came in at $41.5 million versus the consensus estimate of $37.47 million.

For earnings history and earnings-related data on Avadel Pharma (AVDL) click here.